FDA Modifies Mifepristone REMS Program, Establishes Certification Process for Pharmacies | Polsinelli

On January 3, 2023, FDA released an updated Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. The updated REMS follows a December 2021 FDA announcement that it would...

Related Keywords

District Of Columbia ,United States , ,Danco Laboratories Or Genbiopro Inc ,Society Of Maternal ,Practice Group ,Mifepristone Program ,American College Of Obstetricians ,Risk Evaluation ,Mitigation Strategy ,Mifepristone Tablets ,Mifepristone Tablet ,Prescriber Agreement Form ,Patient Agreement Form ,New Modifications ,Information Page ,Danco Laboratories ,Prescriber Agreement Forms ,Pharmacy Agreement Form ,Pharmacy Agreement ,Prescriber Agreement ,American College ,Maternal Fetal Medicine ,Janet Woodstock ,